Amedisys, Inc. (AMED) Reports Mixed Q3 Results; Cuts FY11 EPS Guidance; Announces Strategic Alignment, Mgmt Changes
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Net service revenue: 361.6M
Today's EPS Names:
MAYS, CRMT, REPL, More
Financial Fact:
Net service revenue: 361.6M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Amedisys, Inc. (NASDAQ: AMED) reported Q3 EPS of $0.36, vs. the analyst estimate of $0.50. Revenue for the quarter came in at $374.9 million versus the consensus estimate of $372.06 million.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Castle Biosciences CFO Frank Stokes named Houston Business Journal honoree
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Management Changes, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
